Bruker Hold Rating: Balancing Optimism and Caution Amidst Uncertainties

Analyst Daniel Brennan of TD Cowen maintained a Hold rating on Bruker (BRKR – Research Report), retaining the price target of $45.00.

Daniel Brennan has given his Hold rating due to a combination of factors influencing Bruker’s current and future performance. Despite a notable decline in stock value and a conservative guidance cut, management has shown optimism about certain growth drivers. However, the outlook for 2025 remains cautious, particularly in the US Academic and Government sectors, which are experiencing significant challenges.
Moreover, while the company’s setup appears more favorable following the first quarter results, the anticipated earnings per share reduction and the macroeconomic conditions have already led investors to expect weaker growth and margins. The guidance for 2025 seems to have been adjusted to mitigate risks, but uncertainties remain, especially regarding the US National Institutes of Health funding and the impact of Chinese tariffs. Brennan seeks more clarity on the fourth-quarter margin improvement and the extent of recovery in 2026 before adopting a more positive stance.